Posttreatment serum CXCL10 level stratifies survival in compensated and decompensated cirrhotic patients due to chronic hepatitis C virus infection after direct-acting antiviral therapy
Journal of Gastroenterology · 2025
DOI: 10.1007/s00535-025-02282-4 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Gastroenterology, 2025. Verfasst von Takanori Suzuki und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho, Nagoya, Aichi, 467-86…. Hauptthemen laut MEDLINE: Chemokine CXCL10, Hepatitis C, Chronic, Antiviral Agents, Liver Cirrhosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Gilead Sciences.
Abstract (Originalsprache)
AIM: We investigated the usefulness of serum CXCL10 levels for predicting prognosis in hepatitis C virus (HCV)-infected patients with compensated and decompensated cirrhosis (cLC and dLC) after direct-acting antiviral (DAA) therapy. METHODS: This nationwide multicenter study enrolled 212 HCV-associated LC patients, consisting of 113 cLC and 99 dLC patients, receiving DAA therapy, who had preserved serum samples. Serum CXCL10 levels were measured at pretreatment (pre-CXCL10) and posttreatment (12 or 24 weeks after the end of treatment: EOT12W or EOT24W) (post-CXCL10). We evaluated the relationship between these levels and liver transplantation (LT)-free overall survival (OS) and clinical outcomes. RESULTS: During the observational period (median: 37 months), 27 patients developed dLC events and 20 died. The post-CXCL10 levels were significantly higher in dLC than in cLC (P = 0.006) and among patients who died than those who survived (P < 0.001). The cutoff value of serum post-CXCL10 level for discriminating the occurrence of death (345 pg/mL) could predict LT-free OS in groups of all, cLC, and dLC patients (P < 0.001, P = 0.007, and P < 0.001, respectively). Multivariate analysis on factors associated with LT-free OS demonstrated that age (HR 1.076; P = 0.013), Child-Pugh score at EOT12W (HR 1.575; P = 0.009), and serum post-CXCL10 level (HR 1.003; P = 0.001) were independent factors. CONCLUSIONS: The serum post-CXCL10 level was independently related to survival in HCV-associated LC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho, Nagoya, Aichi, 467-8601, Japan.
- Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho, Nagoya, Aichi, 467-8601, Japan. matsuura@med.nagoya-cu.ac.jp.
- Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
- Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
- First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
- Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Förderung
- Japan Agency for Medical Research and Development
- Gilead Sciences
Zitieren
APA
Suzuki, T., Matsuura, K., Tahata, Y., Hikita, H., Sakamori, R., Kawada, N., Enomoto, N., Miki, D., Yatsuhashi, H., Kuroda, H., Yamashita, T., Yoshiji, H., Kurosaki, M., Mawatari, S., Miyaaki, H., Asahina, Y., Hiasa, Y., Mochida, S., Nakamoto, Y., …, & Takehara, T. (2025). Posttreatment serum CXCL10 level stratifies survival in compensated and decompensated cirrhotic patients due to chronic hepatitis C virus infection after direct-acting antiviral therapy. Journal of Gastroenterology. https://doi.org/10.1007/s00535-025-02282-4
Vancouver
Suzuki T, Matsuura K, Tahata Y, Hikita H, Sakamori R, Kawada N, et al. Posttreatment serum CXCL10 level stratifies survival in compensated and decompensated cirrhotic patients due to chronic hepatitis C virus infection after direct-acting antiviral therapy. Journal of Gastroenterology. 2025. doi:10.1007/s00535-025-02282-4
BibTeX
@article{Suzuki2025,
author = {Suzuki, Takanori and Matsuura, Kentaro and Tahata, Yuki and Hikita, Hayato and Sakamori, Ryotaro and Kawada, Norifumi and Enomoto, Nobuyuki and Miki, Daiki and Yatsuhashi, Hiroshi and Kuroda, Hidekatsu and Yamashita, Taro and Yoshiji, Hitoshi and Kurosaki, Masayuki and Mawatari, Seiichi and Miyaaki, Hisamitsu and Asahina, Yasuhiro and Hiasa, Yoichi and Mochida, Satoshi and Nakamoto, Yasunari and Takami, Taro and Kodama, Takahiro and Tatsumi, Tomohide and Takehara, Tetsuo},
title = {Posttreatment serum CXCL10 level stratifies survival in compensated and decompensated cirrhotic patients due to chronic hepatitis C virus infection after direct-acting antiviral therapy},
journal = {Journal of Gastroenterology},
year = {2025},
doi = {10.1007/s00535-025-02282-4}
}
EUVIMED